Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The company is bringing precision therapies for gynaecological cancers
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Athena is also exploring the use of this technology for expanded carrier screening
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
The submission is supported by results from the Phase 3b APEX study
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Subscribe To Our Newsletter & Stay Updated
